Abstract: Baseline drug resistance to
nucleoside reverse transcriptase inhibitors was observed in 54.5% of cases (mutations:
M41L,
K103N,
T215S/D) with evidence of clustering, no baseline
integrase or
protease resistance and infrequent non-R5 tropism (13.6%).